Polatuzumab‐bendamustine‐rituximab as bridge to CD19‐directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax

• Vincenzo Maria Perriello,
• Lorenza Falini,
• Loredana Ruggeri,
• Daniele Sorcini,
• Stelvio Ballanti,
• Leonardo Flenghi,
• Nicodemo Baffa,
• Piero Covarelli,
• Paolo Sportoletti,
• Antonio Pierini,
• Brunangelo Falini

Affiliations

Vincenzo Maria Perriello

Hematology Section, Department of Medicine and Surgery, Center for Hemato‐Oncological Research (CREO) University of Perugia Perugia Italy

Lorenza Falini

Hematology Section, Department of Medicine and Surgery, Center for Hemato‐Oncological Research (CREO) University of Perugia Perugia Italy

Loredana Ruggeri

Hematology Section, Department of Medicine and Surgery, Center for Hemato‐Oncological Research (CREO) University of Perugia Perugia Italy

Daniele Sorcini

Hematology Section, Department of Medicine and Surgery, Center for Hemato‐Oncological Research (CREO) University of Perugia Perugia Italy

Stelvio Ballanti

Hematology Section, Department of Medicine and Surgery, Center for Hemato‐Oncological Research (CREO) University of Perugia Perugia Italy

Leonardo Flenghi

Hematology Section, Department of Medicine and Surgery, Center for Hemato‐Oncological Research (CREO) University of Perugia Perugia Italy

Nicodemo Baffa

Department of PET‐CT and Radiological and Laboratory Imaging Hospital Santa Maria della Misericordia Perugia Italy

Piero Covarelli

Section of Oncology Surgery, Department of Medicine and Surgery University of Perugia Perugia Italy

Paolo Sportoletti

Hematology Section, Department of Medicine and Surgery, Center for Hemato‐Oncological Research (CREO) University of Perugia Perugia Italy

Antonio Pierini

Hematology Section, Department of Medicine and Surgery, Center for Hemato‐Oncological Research (CREO) University of Perugia Perugia Italy

Brunangelo Falini

Hematology Section, Department of Medicine and Surgery, Center for Hemato‐Oncological Research (CREO) University of Perugia Perugia Italy